Register, NIH Technology Opportunities Webinar: "Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma"

NCI has an exciting technology webinar coming up on March 22nd that addresses a significant unmet medical need in the vision sector. 

We realize the time-zone difference is largely problematic so we will forward a recording of the webinar to all registrants. 

 *아래 내용이 보이지 않는 분께서는 여기를 눌러 등록바랍니다. 

 

NIH Technology Opportunities Webinar: Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma     Register to attend a free NIH webinar. Attendees will learn about a new method for treating glaucoma using exosomes derived from bone marrow-derived mesenchymal stem cells (BMSC).  Webinar Overview: The inventors will discuss their discovery that BMSC‐derived exosome administration for glaucoma may confer a significant neuroprotective effect for retinal ganglion cells (RGCs) and prevent vision loss, and how their isolated BMSC-derived exosomes have several immediate advantages for clinical translation compared to potential whole-cell (stem cell) therapies currently being used to treat glaucoma.     Dr. Stanislav Tomarev, NEI Presenters Stanislav Tomarev, Ph.D.,  Senior Investigator, Retinal Ganglion Cell Biology National Eye Institute (NEI) Ben Mead, Ph.D. Neuroscientist Cardiff University Exosome and Retinal Research Group   Dr. Ben Mead, Cardiff University   About the Featured Technology Glaucoma is one of the world’s leading causes of irreversible blindness. There is no cure and vision lost from glaucoma cannot be restored. Glaucoma is often associated with fluid build-up in the eye resulting in an increased intraocular pressure (IOP). The pressure may cause damage to the optic nerve and lead to progressive degeneration of retinal ganglion cells (RGC) and vision loss. Currently, available treatments for glaucoma delay progression by reducing IOP, but no therapies exist to directly protect RGCs from degradation and loss. This new method of using BMSC-derived exosomes provides a way to directly target and protect RGCs from degrading because of IOP related damage to the optic nerve. This method for protecting RGCs could also be used in combination with other methods for reducing IOP. The NEI is seeking licensing and/or co-development partners for this technology.    Competitive Advantages BMSC-derived exosomes are significantly less expensive than bone marrow-derived mesenchymal stem cells (BMSC). Exosomes can be prepared in large quantities, characterized, and stored for a long time before usage. BMSC-derived exosomes are safer than BMSC. Exosomes, unlike BMSC, have been demonstrated to cross blood brain and blood retinal barriers, proving their potential as potent drug delivery agents. BMSC exosomes represents a treatment alternative to the current BMSC treatment for protecting RGCs.   What attend? Assess co-developing the technology Interact with the inventors, ask questions and provide feedback Learn how to partner with the NIH Who should attend? Business development professionals Drug development professionals Biotech/pharma/academia reseachers Investors and entrepreneurs

   

Stay Connected with the NCI Technology Transfer Center
SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to michael.salgaller@nih.gov using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892